Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 189

1.

Evaluation of integrated care services in Catalonia: population-based and service-based real-life deployment protocols.

Baltaxe E, Cano I, Herranz C, Barberan-Garcia A, Hernandez C, Alonso A, Arguis MJ, Bescos C, Burgos F, Cleries M, Contel JC, de Batlle J, Islam K, Kaye R, Lahr M, Martinez-Palli G, Miralles F, Moharra M, Monterde D, Piera J, Ríos J, Rodriguez N, Ron R, Rutten-van Mölken M, Salas T, Santaeugenia S, Schonenberg H, Solans O, Torres G, Vargiu E, Vela E, Roca J.

BMC Health Serv Res. 2019 Jun 11;19(1):370. doi: 10.1186/s12913-019-4174-2.

2.

The Fold-in, Fold-out Design for DCE Choice Tasks: Application to Burden of Disease.

Goossens LMA, Jonker MF, Rutten-van Mölken MPMH, Boland MRS, Slok AHM, Salomé PL, van Schayck OCP, In 't Veen JCCM, Stolk EA, Donkers B; research team that developed the ABC tool.

Med Decis Making. 2019 May;39(4):450-460. doi: 10.1177/0272989X19849461. Epub 2019 May 29.

3.

Exploring the Impact of Adding a Respiratory Dimension to the EQ-5D-5L.

Hoogendoorn M, Oppe M, Boland MRS, Goossens LMA, Stolk EA, Rutten-van Mölken MPMH.

Med Decis Making. 2019 May;39(4):393-404. doi: 10.1177/0272989X19847983. Epub 2019 May 16.

4.

Clinical outcome and cost-effectiveness of a 1-year nutritional intervention programme in COPD patients with low muscle mass: The randomized controlled NUTRAIN trial.

van Beers M, Rutten-van Mölken MPMH, van de Bool C, Boland M, Kremers SPJ, Franssen FME, van Helvoort A, Gosker HR, Wouters EF, Schols AMWJ.

Clin Nutr. 2019 Mar 18. pii: S0261-5614(19)30114-1. doi: 10.1016/j.clnu.2019.03.001. [Epub ahead of print]

5.

Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results.

Hoogendoorn M, Corro Ramos I, Baldwin M, Luciani L, Fabron C, Detournay B, Rutten-van Mölken MPMH.

Int J Chron Obstruct Pulmon Dis. 2019 Feb 18;14:447-456. doi: 10.2147/COPD.S191031. eCollection 2019.

6.

Broadening the Perspective of Cost-Effectiveness Modeling in Chronic Obstructive Pulmonary Disease: A New Patient-Level Simulation Model Suitable to Evaluate Stratified Medicine.

Hoogendoorn M, Corro Ramos I, Baldwin M, Gonzalez-Rojas Guix N, Rutten-van Mölken MPMH.

Value Health. 2019 Mar;22(3):313-321. doi: 10.1016/j.jval.2018.10.008. Epub 2018 Dec 20.

PMID:
30832969
7.

Planning, implementation and operation of a personalized patient management system for subjects with first suspect of cancer (OnkoNetwork): system description based on a qualitative study.

Pitter JG, Csanádi M, Szigeti A, Lukács G, Kovács Á, Moizs M, Repa I, Zemplényi A, Czypionka T, Kraus M, Rutten-van Mölken MPMH, Kaló Z.

BMC Health Serv Res. 2019 Feb 21;19(1):131. doi: 10.1186/s12913-019-3957-9.

8.

What Is the Potential of Tissue-Engineered Pulmonary Valves in Children?

Huygens SA, Rutten-van Mölken MPMH, Noruzi A, Etnel JRG, Corro Ramos I, Bouten CVC, Kluin J, Takkenberg JJM.

Ann Thorac Surg. 2019 Jun;107(6):1845-1853. doi: 10.1016/j.athoracsur.2018.11.066. Epub 2018 Dec 31.

PMID:
30605643
9.

Bioprosthetic aortic valve replacement in elderly patients: Meta-analysis and microsimulation.

Huygens SA, Etnel JRG, Hanif M, Bekkers JA, Bogers AJJC, Rutten-van Mölken MPMH, Takkenberg JJM.

J Thorac Cardiovasc Surg. 2019 Jun;157(6):2189-2197.e14. doi: 10.1016/j.jtcvs.2018.10.040. Epub 2018 Oct 22.

PMID:
30501946
10.

Beyond the clinical impact of aortic and pulmonary valve implantation: health-related quality of life, informal care and productivity†.

Huygens SA, van der Kley F, Bekkers JA, Bogers AJJC, Takkenberg JJM, Rutten-van Mölken MPMH.

Eur J Cardiothorac Surg. 2019 Apr 1;55(4):751-759. doi: 10.1093/ejcts/ezy382.

PMID:
30496373
11.

Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis.

Alemao E, Al MJ, Boonen AA, Stevenson MD, Verstappen SMM, Michaud K, Weinblatt ME, Rutten-van Mölken MPMH.

PLoS One. 2018 Oct 5;13(10):e0205013. doi: 10.1371/journal.pone.0205013. eCollection 2018.

12.

Defining good health and care from the perspective of persons with multimorbidity: results from a qualitative study of focus groups in eight European countries.

Leijten FRM, Hoedemakers M, Struckmann V, Kraus M, Cheraghi-Sohi S, Zemplényi A, Ervik R, Vallvé C, Huiĉ M, Czypionka T, Boland M, Rutten-van Mölken MPMH; SELFIE consortium.

BMJ Open. 2018 Aug 30;8(8):e021072. doi: 10.1136/bmjopen-2017-021072.

13.

Strengthening the evidence-base of integrated care for people with multi-morbidity in Europe using Multi-Criteria Decision Analysis (MCDA).

Rutten-van Mölken M, Leijten F, Hoedemakers M, Tsiachristas A, Verbeek N, Karimi M, Bal R, de Bont A, Islam K, Askildsen JE, Czypionka T, Kraus M, Huic M, Pitter JG, Vogt V, Stokes J, Baltaxe E; SELFIE consortium.

BMC Health Serv Res. 2018 Jul 24;18(1):576. doi: 10.1186/s12913-018-3367-4. Review.

14.

Towards incentivising integration: A typology of payments for integrated care.

Stokes J, Struckmann V, Kristensen SR, Fuchs S, van Ginneken E, Tsiachristas A, Rutten van Mölken M, Sutton M.

Health Policy. 2018 Sep;122(9):963-969. doi: 10.1016/j.healthpol.2018.07.003. Epub 2018 Jul 11. Review.

15.

How much does a heart valve implantation cost and what are the health care costs afterwards?

Huygens SA, Goossens LMA, van Erkelens JA, Takkenberg JJM, Rutten-van Mölken MPMH.

Open Heart. 2018 Feb 14;5(1):e000672. doi: 10.1136/openhrt-2017-000672. eCollection 2018. Erratum in: Open Heart. 2018 Apr 5;5(1):e000672corr1.

16.

Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor Prognosis.

Alemao E, Johal S, Al MJ, Rutten-van Mölken M.

Value Health. 2018 Feb;21(2):193-202. doi: 10.1016/j.jval.2017.05.020. Epub 2017 Jul 1.

17.

ABC Index: quantifying experienced burden of COPD in a discrete choice experiment and predicting costs.

Goossens LMA, Rutten-van Mölken MPMH, Boland MRS, Donkers B, Jonker MF, Slok AHM, Salomé PL, van Schayck OCP, In 't Veen JCCM, Stolk EA; research team that developed the ABC tool.

BMJ Open. 2017 Dec 26;7(12):e017831. doi: 10.1136/bmjopen-2017-017831.

18.

Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines.

Ramos IC, Versteegh MM, de Boer RA, Koenders JMA, Linssen GCM, Meeder JG, Rutten-van Mölken MPMH.

Value Health. 2017 Dec;20(10):1260-1269. doi: 10.1016/j.jval.2017.05.013. Epub 2017 Jun 20.

19.

Prediction models for exacerbations in different COPD patient populations: comparing results of five large data sources.

Hoogendoorn M, Feenstra TL, Boland M, Briggs AH, Borg S, Jansson SA, Risebrough NA, Slejko JF, Rutten-van Mölken MP.

Int J Chron Obstruct Pulmon Dis. 2017 Nov 1;12:3183-3194. doi: 10.2147/COPD.S142378. eCollection 2017.

20.

PRIORITIES FOR HEALTH ECONOMIC METHODOLOGICAL RESEARCH: RESULTS OF AN EXPERT CONSULTATION.

Tordrup D, Chouaid C, Cuijpers P, Dab W, van Dongen JM, Espin J, Jönsson B, Léonard C, McDaid D, McKee M, Miguel JP, Patel A, Reginster JY, Ricciardi W, Rutten-van Molken M, Rupel VP, Sach T, Sassi F, Waugh N, Bertollini R.

Int J Technol Assess Health Care. 2017 Jan;33(6):609-619. doi: 10.1017/S0266462317000666. Epub 2017 Oct 30.

21.

Relevant models and elements of integrated care for multi-morbidity: Results of a scoping review.

Struckmann V, Leijten FRM, van Ginneken E, Kraus M, Reiss M, Spranger A, Boland MRS, Czypionka T, Busse R, Rutten-van Mölken M; SELFIE consortium.

Health Policy. 2018 Jan;122(1):23-35. doi: 10.1016/j.healthpol.2017.08.008. Epub 2017 Oct 6. Review.

22.

Common challenges faced in EU-funded projects on integrated care for vulnerable persons.

Rutten-van Mölken M.

Int J Integr Care. 2017 Jun 28;17(2):17. doi: 10.5334/ijic.3104. No abstract available.

23.

Assessment of Burden of COPD tool: evidence not perception.

Slok AHM, Kotz D, van Breukelen G, Chavannes NH, Rutten-van Mölken MPMH, Kerstjens HAM, van der Molen T, Asijee GM, Dekhuijzen PNR, Holverda S, Salomé PL, Goossens LMA, Twellaar M, In 't Veen JCCM, van Schayck OCP.

Eur Respir J. 2017 Jul 27;50(1). pii: 1700756. doi: 10.1183/13993003.00756-2017. Print 2017 Jul. No abstract available.

24.

The SELFIE framework for integrated care for multi-morbidity: Development and description.

Leijten FRM, Struckmann V, van Ginneken E, Czypionka T, Kraus M, Reiss M, Tsiachristas A, Boland M, de Bont A, Bal R, Busse R, Rutten-van Mölken M; SELFIE consortium.

Health Policy. 2018 Jan;122(1):12-22. doi: 10.1016/j.healthpol.2017.06.002. Epub 2017 Jun 20.

25.

Performing Economic Evaluation of Integrated Care: Highway to Hell or Stairway to Heaven?

Tsiachristas A, Stein KV, Evers S, Rutten-van Mölken M.

Int J Integr Care. 2016 Oct 19;16(4):3. doi: 10.5334/ijic.2472.

26.

External Validation of Health Economic Decision Models for Chronic Obstructive Pulmonary Disease (COPD): Report of the Third COPD Modeling Meeting.

Hoogendoorn M, Feenstra TL, Asukai Y, Briggs AH, Hansen RN, Leidl R, Risebrough N, Samyshkin Y, Wacker M, Rutten-van Mölken MP.

Value Health. 2017 Mar;20(3):397-403. doi: 10.1016/j.jval.2016.10.016. Epub 2017 Jan 3.

27.

Systematic review of model-based economic evaluations of heart valve implantations.

Huygens SA, Takkenberg JJM, Rutten-van Mölken MPMH.

Eur J Health Econ. 2018 Mar;19(2):241-255. doi: 10.1007/s10198-017-0880-z. Epub 2017 Mar 6. Review.

28.

Mix and match. A simulation study on the impact of mixed-treatment comparison methods on health-economic outcomes.

Vemer P, Al MJ, Oppe M, Rutten-van Mölken MP.

PLoS One. 2017 Feb 2;12(2):e0171292. doi: 10.1371/journal.pone.0171292. eCollection 2017.

29.

Comparison of cardiovascular risk algorithms in patients with vs without rheumatoid arthritis and the role of C-reactive protein in predicting cardiovascular outcomes in rheumatoid arthritis.

Alemao E, Cawston H, Bourhis F, Al M, Rutten-van Molken M, Liao KP, Solomon DH.

Rheumatology (Oxford). 2017 May 1;56(5):777-786. doi: 10.1093/rheumatology/kew440.

PMID:
28087832
30.

Comprehensive Diagnostic Assessment of Health Status of Patients with Asthma or COPD: A Delphi Panel Study among Dutch Experts.

van den Akker EF, Van't Hul AJ, Birnie E, Chavannes NH, Rutten-van Mölken MP, In't Veen JC.

COPD. 2017 Apr;14(2):190-199. doi: 10.1080/15412555.2016.1264378. Epub 2016 Dec 27.

PMID:
28026983
31.

'To use or not to use': a qualitative study to evaluate experiences of healthcare providers and patients with the assessment of burden of COPD (ABC) tool.

Slok AH, Twellaar M, Jutbo L, Kotz D, Chavannes NH, Holverda S, Salomé PL, Dekhuijzen PN, Rutten-van Mölken MP, Schuiten D, In 't Veen JC, van Schayck OC.

NPJ Prim Care Respir Med. 2016 Nov 17;26:16074. doi: 10.1038/npjpcrm.2016.74.

32.

Conceptual model for early health technology assessment of current and novel heart valve interventions.

Huygens SA, Rutten-van Mölken MP, Bekkers JA, Bogers AJ, Bouten CV, Chamuleau SA, de Jaegere PP, Kappetein AP, Kluin J, van Mieghem NM, Versteegh MI, Witsenburg M, Takkenberg JJ.

Open Heart. 2016 Oct 14;3(2):e000500. eCollection 2016.

33.

[Effectiveness of the Assessment of Burden of COPD tool: a cluster-randomised controlled trial].

van Schayck OC, Slok AH, Kotz D, van Breukelen G, Chavannes NH, Rutten-van Mölken MP, Kerstjens HA, van der Molen T, Asijee GM, Dekhuijzen PN, Holverda S, Salomé PL, Goossens LM, Twellaar M, In 't Veen JC.

Ned Tijdschr Geneeskd. 2016;160:D955. Dutch.

PMID:
27805538
34.

Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease: Are Current Models Suitable to Evaluate Personalized Medicine?

Hoogendoorn M, Feenstra TL, Asukai Y, Briggs AH, Borg S, Dal Negro RW, Hansen RN, Jansson SA, Leidl R, Risebrough N, Samyshkin Y, Wacker ME, Rutten-van Mölken MPMH.

Value Health. 2016 Sep - Oct;19(6):800-810. doi: 10.1016/j.jval.2016.04.002. Epub 2016 May 21.

35.

Systematic Review and Quality Appraisal of Cost-Effectiveness Analyses of Pharmacologic Maintenance Treatment for Chronic Obstructive Pulmonary Disease: Methodological Considerations and Recommendations.

van der Schans S, Goossens LMA, Boland MRS, Kocks JWH, Postma MJ, van Boven JFM, Rutten-van Mölken MPMH.

Pharmacoeconomics. 2017 Jan;35(1):43-63. doi: 10.1007/s40273-016-0448-2. Review.

36.

Development of a Conceptual Model of Disease Progression for Use in Economic Modeling of Chronic Obstructive Pulmonary Disease.

Tabberer M, Gonzalez-McQuire S, Muellerova H, Briggs AH, Rutten-van Mölken MPMH, Chambers M, Lomas DA.

Med Decis Making. 2017 May;37(4):440-452. doi: 10.1177/0272989X16662009. Epub 2016 Aug 2.

PMID:
27486218
37.

Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy.

Selya-Hammer C, Gonzalez-Rojas Guix N, Baldwin M, Ternouth A, Miravitlles M, Rutten-van Mölken M, Goosens LM, Buyukkaramikli N, Acciai V.

Ther Adv Respir Dis. 2016 Oct;10(5):391-401. doi: 10.1177/1753465816657272. Epub 2016 Jul 12.

38.

Effectiveness of the Assessment of Burden of COPD (ABC) tool on health-related quality of life in patients with COPD: a cluster randomised controlled trial in primary and hospital care.

Slok AH, Kotz D, van Breukelen G, Chavannes NH, Rutten-van Mölken MP, Kerstjens HA, van der Molen T, Asijee GM, Dekhuijzen PN, Holverda S, Salomé PL, Goossens LM, Twellaar M, In 't Veen JC, van Schayck OC.

BMJ Open. 2016 Jul 11;6(7):e011519. doi: 10.1136/bmjopen-2016-011519.

39.

Development of the Galaxy Chronic Obstructive Pulmonary Disease (COPD) Model Using Data from ECLIPSE: Internal Validation of a Linked-Equations Cohort Model.

Briggs AH, Baker T, Risebrough NA, Chambers M, Gonzalez-McQuire S, Ismaila AS, Exuzides A, Colby C, Tabberer M, Muellerova H, Locantore N, Rutten van Mölken MPMH, Lomas DA.

Med Decis Making. 2017 May;37(4):469-480. doi: 10.1177/0272989X16653118. Epub 2016 Jun 17.

PMID:
27317436
40.

A five-year model to assess the early cost-effectiveness of new diagnostic tests in the early diagnosis of rheumatoid arthritis.

Buisman LR, Luime JJ, Oppe M, Hazes JM, Rutten-van Mölken MP.

Arthritis Res Ther. 2016 Jun 10;18(1):135. doi: 10.1186/s13075-016-1020-3.

41.

e-Monitoring of Asthma Therapy to Improve Compliance in children (e-MATIC): a randomised controlled trial.

Vasbinder EC, Goossens LM, Rutten-van Mölken MP, de Winter BC, van Dijk L, Vulto AG, Blankman EI, Dahhan N, Veenstra-van Schie MT, Versteegh FG, Wolf BH, Janssens HM, van den Bemt PM.

Eur Respir J. 2016 Sep;48(3):758-67. doi: 10.1183/13993003.01698-2015. Epub 2016 May 26.

42.

Contemporary outcomes after surgical aortic valve replacement with bioprostheses and allografts: a systematic review and meta-analysis.

Huygens SA, Mokhles MM, Hanif M, Bekkers JA, Bogers AJ, Rutten-van Mölken MP, Takkenberg JJ.

Eur J Cardiothorac Surg. 2016 Oct;50(4):605-616. Epub 2016 Mar 29. Review.

43.

THE EARLY BIRD CATCHES THE WORM: EARLY COST-EFFECTIVENESS ANALYSIS OF NEW MEDICAL TESTS.

Buisman LR, Rutten-van Mölken MP, Postmus D, Luime JJ, Uyl-de Groot CA, Redekop WK.

Int J Technol Assess Health Care. 2016 Jan;32(1-2):46-53. doi: 10.1017/S0266462316000064. Epub 2016 Mar 22.

PMID:
27002226
44.

Impact of financial agreements in European chronic care on health care expenditure growth.

Tsiachristas A, Dikkers C, Boland MR, Rutten-van Mölken MP.

Health Policy. 2016 Apr;120(4):420-30. doi: 10.1016/j.healthpol.2016.02.012. Epub 2016 Mar 2.

PMID:
26971018
45.

The Assessment of Burden of COPD (ABC) Scale: A Reliable and Valid Questionnaire.

Slok AH, Bemelmans TC, Kotz D, van der Molen T, Kerstjens HA, In 't Veen JC, Chavannes NH, Asijee GM, Rutten-van Mölken MP, van Schayck OC.

COPD. 2016 Aug;13(4):431-8. doi: 10.3109/15412555.2015.1118025. Epub 2016 Jan 20.

PMID:
26788838
46.

Current and Future Incidence and Costs of Osteoporosis-Related Fractures in The Netherlands: Combining Claims Data with BMD Measurements.

Lötters FJ, van den Bergh JP, de Vries F, Rutten-van Mölken MP.

Calcif Tissue Int. 2016 Mar;98(3):235-43. doi: 10.1007/s00223-015-0089-z. Epub 2016 Jan 9.

47.

Cardiovascular risk factor management in patients with RA compared to matched non-RA patients.

Alemao E, Cawston H, Bourhis F, Al M, Rutten-van Mölken MP, Liao KP, Solomon DH.

Rheumatology (Oxford). 2016 May;55(5):809-16. doi: 10.1093/rheumatology/kev427. Epub 2015 Dec 24.

48.

Cost-Effectiveness of Disease Management Programs for Cardiovascular Risk and COPD in The Netherlands.

Tsiachristas A, Burgers L, Rutten-van Mölken MP.

Value Health. 2015 Dec;18(8):977-86. doi: 10.1016/j.jval.2015.07.007. Epub 2015 Sep 16.

49.

Exploring the variation in implementation of a COPD disease management programme and its impact on health outcomes: a post hoc analysis of the RECODE cluster randomised trial.

Boland MR, Kruis AL, Huygens SA, Tsiachristas A, Assendelft WJ, Gussekloo J, Blom CM, Chavannes NH, Rutten-van Mölken MP.

NPJ Prim Care Respir Med. 2015 Dec 17;25:15071. doi: 10.1038/npjpcrm.2015.71.

50.

Investigating the association between medication adherence and health-related quality of life in COPD: Methodological challenges when using a proxy measure of adherence.

Boland MR, van Boven JF, Kruis AL, Chavannes NH, van der Molen T, Goossens LM, Rutten-van Mölken MP.

Respir Med. 2016 Jan;110:34-45. doi: 10.1016/j.rmed.2015.11.008. Epub 2015 Nov 23.

Supplemental Content

Loading ...
Support Center